Aclaris Therapeutics vs Upstream Bio
ACRS and UPB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACRS and UPB compare
Aclaris Therapeutics is the larger company, worth 3.1 times as much as Upstream Bio ($584M against $187M).
Upstream Bio grew revenue faster over the last twelve months (16.0% versus −51.0% for Aclaris Therapeutics).
Aclaris Therapeutics keeps more of each dollar of sales as profit, with a net margin of −921% compared with −4956% at Upstream Bio.
Upstream Bio scores higher on the StockData Score (9 against 5 for Aclaris Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACRS | UPB |
|---|---|---|
| Size and price | ||
| Market cap | $584M | $187M |
| Share price | $3.97 | $3.41 |
| Change, 1 year | 69.7% | −85.9% |
| Change, 5 years | −75.9% | – |
| Beta (5Y) | 1.15 | 1.47 |
| Employees | 73 | 75 |
| StockData Score | ||
| Total score | 5 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 71.1× | 59.1× (better) |
| P/B | 4.7× | 0.7× (better) |
| FCF yield | −10.6% | – |
| Fair value | $1.45 | – |
| Margin of safety | −173% | – |
| Growth | ||
| Revenue growth (TTM) | −51.0% | 16.0% (better) |
| Revenue growth, 5Y average | 3.8% | – |
| Profitability | ||
| Gross margin | 79.5% | – |
| Operating margin | −1050% (better) | −5383% |
| Net margin | −921% (better) | −4956% |
| FCF margin | −757% | – |
| Return on equity | −59.1% | −46.0% (better) |
| Return on invested capital | – | −1082% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 3.46 | 27.99 (better) |
| Altman Z-score | −2.58 | 8.07 (better) |
| Piotroski F-score | 3 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 82.3% | 92.3% |
| Held by insiders | 13.3% | 8.6% |
| Insider net buying, 12 months | −$1.4M | −$105K (better) |
| Short interest, % of float | 14.2% | 9.0% |
Go deeper
- ACRS stock overview
- ACRS income statement
- ACRS valuation and score
- UPB stock overview
- UPB income statement
- UPB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.